Biomarker Testing and Access Barriers in EGFR-Mutated NSCLC

August 20, 2026

Several practical barriers stand between EGFR-mutated advanced non-small cell lung cancer patients and the care described earlier in this discussion. Requests for second opinions and referrals to academic centers are treated as reasonable and worth accommodating, though keeping track of which clinical trials are open at any moment remains difficult, and artificial intelligence matching tools are a hope rather than a working solution. Comprehensive biomarker testing carries equal weight: a young never-smoker whose first next-generation sequencing pass finds no driver warrants both DNA and RNA testing, along with MET and HER2 immunohistochemistry, given that approved therapies exist for those targets. Reimbursement proves less limiting once a drug is approved, though denials and co-pays remain real enough that assistance programs matter. The closing outlook is a field moving past EGFR alone toward resistance-driven, personalized selection, more complicated than before but also more promising.